Cigna Beats Q3, Lifts 2026 Guidance, but Flags 2027 Rebate and GLP-1 Headwinds
CI sits 18% above its 52-week low of $255.528.
Summary
Cigna beat on both lines: adjusted EPS of $7.98 versus $7.50 consensus and revenue of $73.683 billion, up 6% year over year and ahead of the $72.720 billion expected. It raised 2026 adjusted earnings guidance to at least $30.60 a share from at least $30.45, and narrowed its 2026 medical care ratio outlook to 84.2% plus or minus 25 basis points. The stock is trading slightly lower, and the reason is 2027: management flagged shrinking industry rebate pools, lower employer coverage of GLP-1 weight-loss drugs at Evernorth's PBM, fewer biosimilar and specialty generic launches, and the previously announced ACA Exchange exit removing that revenue. Offsetting that, Cigna still expects at least 10% adjusted EPS growth in 2027, backed by better stop-loss margins, a strong selling season and savings from its Accelerate to One productivity program. Membership is the soft spot — total customer relationships fell 6% to 177.6 million, with behavioral customers down 19% to 23 million after a government contract ended, while medical customers rose 2% to 18.5 million.
At the time of this announcement, CI was trading at $302.34 on NYSE in the Finance sector, with a market capitalization of approximately $79.9B. The 52-week trading range was $255.53 to $318.05. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.